SUBSCRIBE
SUBSCRIBE
News   Drug Development

Analyst: Roche May Drop Taspoglutide Diabetes Drug

June 28, 2010 | 
1 min read
IndyStar -- Roche Holding AG may drop development of the taspoglutide diabetes drug and return the rights to developer Ipsen SA because the treatment has too many side effects, Morgan Stanley analysts said.
Clinical research Phase 2
Roche
MORE ON THIS TOPIC
Opportunity of winning. man sees a illuminated trophy door. vector
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Human kidney made out of lines. Medical Concept. 3D Rendering.
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
 · 
2 min read
 · 
Annalee Armstrong
Microscope icon. Molecule and communication background. Connected lines with dots.
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
ALS
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS
September 23, 2026
 · 
4 min read
 · 
Heather McKenzie